Publications

Snell Taylor SJ, Nielson CM, Breskin A, Saul B, Yu Y, Alam N, … Kelsh M, et al. 2021. Effectiveness and safety of romiplostim among patients with newly diagnosed, persistent and chronic immune thrombocytopenia in European clinical practice. Adv Ther 38(5):2673–2688.

McGrath LJ, Nielson C, Saul B, Breskin A, Yu Y, Nicolaisen SK, … Kelsh M, et al. 2021. Lessons learned using real-world data to emulate randomized trials: A case study of treatment effectiveness for newly diagnosed immune thrombocytopenia. Clin Pharmacol Ther 110(6):1570–1578; doi: 10.1002/cpt.2399.

Haddadin Z, Rankin DA, Lipworth L, Suh M, McHenry R, Blozinski A, Salib George S, Fernandez KN, Varjabedian R, Spieker AJ, Shepard DS, Halasa NB. 2021. Respiratory virus surveillance in infants across different clinical settings. J Pediat 234:164-171; doi: 10.1016/j.jpeds.2021.03.036.

Vágó EK, Nicholson G, Horváth-Puhó E. Hooda N, Fryzek JP, Su J. 2021. Healthcare resource utilization among patients with cold agglutinin disease in Denmark. Curr Med Res Opin 37(10):1829-1835; doi: 10.1080/03007995.2021.1960494.

Dean R, Jensen IS, Cyr PL, Miller B, Maru B, Sproule DM, Feltner DE, et al. 2021. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER). J Mark Access Health Pol 9(1):1889841; doi: 10.1080/20016689.2021.1889841.

Proctor DM, Bhat V, Suh M, Reichert H, Jiang X, Thompson CM. 2021. Inhalation cancer risk assessment for environmental exposure to hexavalent chromium: Comparison of margin-of-exposure and linear extrapolation approaches. Regul Toxicol Pharmacol 124(Aug):104969; doi: 10.1016/j.yrtph.2021.104969.

Nielson CM, Bylsma LC, Fryzek JP, Saad HA, Crawford J. 2021. Relative dose intensity of chemotherapy and survival in patients with advanced stage solid tumor cancer: A systematic review and meta-analysis. The Oncologist 26(9):e1609–e1618; doi: 10.1002/onco.13822.

Sacks NC, Healey BE, Cyr PL, Slocomb T, James E, Beggs AH, Graham RJ. 2021. Costs and health resource use in patients with X-linked myotubular myopathy: insights from U.S. commercial claims. J Manag Care Spec Pharm 27(8):1019–1026.

Chew D, Sacks NC, Emden MR, Preib MT, Cyr PL, Wood D, Pokorney SD. 2021. Trends in health care resource use and expenditures in patients with newly diagnosed paroxysmal supraventricular tachycardia in the United States. Am Heart J 132–140.

Rehorn M, Sacks NC, Emden MR, Healey B, Preib MT, Cyr PL, Pokorney SD. 2021. Prevalence and incidence of patients with paroxysmal supraventricular tachycardia in the United States. J Cardiovasc Electrophysiol 32(8):2199-2206; doi: 10.1111/jce.15109.